Faron Pharma celebrates positive read-out in ongoing MDS trial
(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer.
Read moreFri, 14th Dec 2018 15:57
(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:
Read more(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder.
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder.
Read more(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cancer treatment.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreWednesday 3 April | |
Downing Strategic Micro-Cap Investment Trust PLC | GM re approval of B share scheme |
Quantum Exponential Group PLC | GM re delisting or potential investment in company |
Thursday 4 April | |
Rio Tinto PLC | AGM |
Scottish American Investment Co PLC | AGM |
TheWorks.co.uk PLC | GM re Main Market delisting and AIM admission |
Friday 5 April | |
Faron Pharmaceuticals Ltd | AGM |
VPC Specialty Lending Investments PLC | GM re capital return via B share scheme |
Monday 8 April | |
Premier African Minerals Ltd | AGM |
Tuesday 9 April | |
Ethernity Networks Ltd | EGM re board appointments and option grants |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate decisions from central banks across the world this week.
Read more(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study focused on myelodysplastic syndrome, or MDS.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more